
PRAX Stock Forecast & Price Target
PRAX Analyst Ratings
Bulls say
Praxis Precision Medicine is supported by a diversified CNS pipeline with four clinical-stage assets and two proprietary platforms, giving it multiple shots on goal across movement disorders and epilepsy. Ulixacaltamide looks increasingly de-risked, with all four FDA-requested sensitivity analyses statistically significant, a long-term snapshot showing ADL gains rising from about 3 points at week 12 to roughly 6 points by week 95, and launch infrastructure already in place ahead of its 1/29/27 PDUFA. Relutrigine adds further upside with 53% placebo-adjusted seizure reduction, about 86% long-term seizure reduction at 18 months, and a broad DEE catalyst in 4Q26, while management also points to a combined $20B+ peak sales vision across the first four assets.
Bears say
Praxis Precision Medicine is viewed negatively because its valuation depends on a series of binary regulatory and clinical outcomes, including ulixacaltamide’s ongoing FDA review, possible DEA scheduling, relutrigine’s EMERALD data in 4Q26, and vormatrigine’s next steps after the POWER1 failure and restarted POWER2. The company also faces execution risk from management’s $20B+ peak sales guidance, while concerns around trial design, statistical analyses, functional unblinding, safety/tolerability, and limited differentiation versus standard of care raise the odds of weaker-than-expected uptake if approved. Financially, it is still a cash-burning biotech with significant R&D and SG&A outlays and likely needs capital markets access, so any regulatory setback or commercial delay could quickly pressure the shares.
This aggregate rating is based on analysts' research of Praxis Precision Medicines and is not a guaranteed prediction by Public.com or investment advice.
PRAX Analyst Forecast & Price Prediction
Start investing in PRAX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Praxis Precision Medicines (PRAX) Forecast
PRAX Analyst Forecast & Price Prediction
Start investing in PRAX
Order type
Buy in
Order amount
Est. shares
0 shares